Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined type 2 diabetes mellitus
As a result, we eat less because we are thinking less about food, and we are satisfied with smaller portions even if we werent overeating
Eligibility typically includes individuals with a body mass index (BMI) of 30 or higher , or a BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
However, while semaglutide can be an effective tool, it is not a stand-alone solution
Nausea and GI effects are most pronounced during the first 2 to 3 weeks at each new dose level, then typically moderate
6.3 Clinical applications in cardiovascular disease prevention Recent American College of Cardiology/American Heart Association guidelines advocate for the use of GLP-1RAs in patients with T2DM at high risk of atherosclerotic cardiovascular disease (ASCVD), irrespective of well-controlled glucose levels, based on the clinical trials mandated by FDA-issued industry guidelines in December 2008 to assess the cardiovascular effects of new diabetic therapies (247)